Session Information
-
WCLC 2018
19th World Conference on Lung Cancer
Conference Program for the 19th World Conference on Lung Cancer in Toronto, Canada
Download PDF of the Abstract Book: Click Here.
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2391
September 23 Sun
Sep 23 Monday
September 24 Mon
Sep 24 Tuesday
September 25 Tue
Sep 25 Wednesday
September 26 Wed
Sep 26
-
+
P2.13 - Targeted Therapy (Not CME Accredited Session)
- 16:45 - 18:00
- 9/25/2018
- Location: Exhibit Hall
- Type: Poster Viewing in the Exhibit Hall
- Track:
-
+
P2.13-01 - Brigatinib Use in England – Where Next?
16:45 - 18:00 | Presenter: Fabio Gomes | Author(s): Kent Yip, Fiona Blackhall, Alastair Greystoke, Raffaele Califano, Sharmistha Ghosh, Thomas Newsom-Davis, Henrietta Mills, Samreen Ahmed, Amelie Harle, Yvonne Summers
- Abstract
Loading... -
+
P2.13-02 - ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.
16:45 - 18:00 | Presenter: Oscar Grundberg | Author(s): Signe Friesland, Samy Abdel-Halim, Sebastian Gagatek, Reza Karimi, Anna Öjdahl-Boden, Georgios Tsakonas, Maja Bradic-Lindh, Karl-Gustav Kölbeck, Gunnar Wagenius, Simon Ekman, Karin Lindberg, Luigi De Petris
- Abstract
Loading... -
+
P2.13-03 - Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
16:45 - 18:00 | Presenter: Maximilian Johannes Hochmair | Author(s): Jakob Naber, Sophia Schwab, Ulrike Setinek, Dagmar Krenbek, Marcel Holzer, Hannah Fabikan, Stefan Watzka, Renate Koger, Andreas Fazekas, Erwin Bitterlich, Arschang Valipour, Otto Chris Burghuber
- Abstract
Loading... -
+
P2.13-04 - Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.
16:45 - 18:00 | Presenter: Di Ma | Author(s): Puyuan Xing, Qiang Wang, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Li Liang, Hongge Liang, Yang Du, Zhaohui Zhang, Junling Li
- Abstract
Loading... -
+
P2.13-05 - Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.
16:45 - 18:00 | Presenter: Di Ma | Author(s): Puyuan Xing, Qiang Wang, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Li Liang, Hongge Liang, Yang Du, Zhaohui Zhang, Junling Li
- Abstract
Loading... -
+
P2.13-06 - TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC
16:45 - 18:00 | Presenter: Paola Ulivi | Author(s): Matteo Canale, Angelo Delmonte, Claudio Dazzi, Alessandro Gamboni, Maurizio Puccetti, Sara Bravaccini, Claudia Casanova, Maximilian Papi, Marita Mariotti, Nicoletta De Luigi, Gabriele Minuti, Daniele Calistri, Massimiliano Bonafè, Lucio Crinò
- Abstract
Loading... -
+
P2.13-07 - CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Kaihua Lu | Author(s): Meiling Zhang, Qian Wang, Yan Ding, Guoqun Wang, Yunqian Chu, Xiang He, Xue Wu, Yang W. Shao
- Abstract
Loading... -
+
P2.13-09 - Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials
16:45 - 18:00 | Presenter: Luiz H. Araujo | Author(s): Gilberto Castro Jr, Pedro De Marchi, Clarissa Baldotto, Gustavo Werutsky, Giuliano Borges, Clarissa Mathias, Aknar Calabrich, Cassia Costa, Fabio Andre Franke, Ellias Lima, Yeni Neron, Gilberto Schwartsmann, Marcelo Graziano Custodio, Cristiane Sansevero, Helano Carioca Freitas
- Abstract
Loading... -
+
P2.13-10 - Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
16:45 - 18:00 | Presenter: Lauren Byers | Author(s): Kathryn Gold, Julio Peguero, Melissa L. Johnson, Jorge Nieva, Wael A Harb, Alberto A. Chiappori, James Strauss, David E Gerber
- Abstract
Loading... -
+
P2.13-11 - EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)
16:45 - 18:00 | Presenter: Andrés F. Cardona | Author(s): Alejandro Ruiz-Patiño, Christian David Castro, Leonardo Rojas, Oscar Arrieta, Zyanya Lucia Zatarain-Barrón, Hernan Carranza, Carlos Vargas, Jorge Otero, Luis Corrales, Claudio Martin, Rafael Rosell
- Abstract
Loading... -
+
P2.13-12 - The deNovo T790M Mutation Recovered by ddPCR is Associated with a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.
16:45 - 18:00 | Presenter: Yoon Soo Chang | Author(s): Eun Young Kim, Arum Kim
- Abstract
Loading... -
+
P2.13-13 - Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis
16:45 - 18:00 | Presenter: Parneet Kaur Cheema | Author(s): Geoffrey Liu, Ronald Burkes, Scott Owen, Joanne Yu, Desiree Hao, Jeffrey Rothenstein, Simon Martel, Mussawar Iqbal, Rosalyn Juergens, Wendy Lam, Janessa Laskin
- Abstract
Loading... -
+
P2.13-14 - The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
16:45 - 18:00 | Presenter: Joanna Chorostowska-Wynimko | Author(s): Adam Szpechcinski, Katarzyna Duk, Maciej Bryl, Grzegorz Czyzewicz, Emil Wojda, Mateusz Florczuk, Pawel Sliwinski, Aleksander Barinow-Wojewodzki
- Abstract
Loading... -
+
P2.13-15 - Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
16:45 - 18:00 | Presenter: Yun Fan | Author(s): Yanjun Xu, Xiaoling Tong, Junrong Yan, Xue Wu, Yang W. Shao
- Abstract
Loading... -
+
P2.13-16 - Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China
16:45 - 18:00 | Presenter: Wenhua Liang | Author(s): Minzhang Guo, Weizhe Huang, Yi Zhao, Jianxing He
- Abstract
Loading... -
+
P2.13-17 - Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder
16:45 - 18:00 | Presenter: ChienHui He | Author(s): Yuh-Min Chen
- Abstract
Loading... -
+
P2.13-18 - A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing
16:45 - 18:00 | Presenter: Eiji Iwama | Author(s): Kazuko Sakai, Koichi Azuma, Daijiro Harada, Kaname Nosaki, Katsuyuki Hotta, Makoto Nishio, Takayasu Kurata, Tatsuro Fukuhara, Hiroaki Akamatsu, Koichi Goto, Takayuki Shimose, Junji Kishimoto, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
- Abstract
Loading... -
+
P2.13-19 - Prognostic Value Inferred from the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients
16:45 - 18:00 | Presenter: Mi-hyun Kim | Author(s): Insu Kim, Jung Seop Eom, Min Ki Lee
- Abstract
Loading... -
+
P2.13-20 - The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis
16:45 - 18:00 | Presenter: Yao-Wen Kuo | Author(s): Chou-Han Lin, Chao-Chi Ho
- Abstract
Loading... -
+
P2.13-21 - MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Xue Lin Kwang | Author(s): Dawn Lau, Audrey-Ann Liew, Yuan Ju, Edwin Lim, Gillianne G.Y. Lai, Rahul Nahar, Yvonne Teng, Khi Pin Chua, Jacob Alvarez, Ming Jie Lim, Hui Sun Leong, Fui Teen Chong, Darren Toh, Hong Sheng Quah, Lisda Suteja, Lan Ying Wang, Kiat Hon Lim, Wan-Teck Lim, Eng-Huat Tan, Wei Wei Zhai, Wai Leong Tam, N Gopalakrishna Iyer, Daniel S.W. Tan
- Abstract
Loading... -
+
P2.13-22 - Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
16:45 - 18:00 | Presenter: Jae Cheol Lee | Author(s): Sei-Hoon Yang, Dong Kyu Oh
- Abstract
Loading... -
+
P2.13-23 - Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
16:45 - 18:00 | Presenter: Haiyan Li | Author(s): Haihua Yang, Kai Wang, Xiaomai Wu, Feng-Ming Spring Kong, Dongqing Lv
- Abstract
Loading... -
+
P2.13-24 - Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients
16:45 - 18:00 | Presenter: Jordi Remon | Author(s): Cecile Jovelet, Ludovic Lacroix, David Planchard, Laura Mezquita, Karen Howarth, Emma Green, Vincent Plagnol, Clive Morris, Nitzan Rosenfeld, Caroline Caramella, Cecile Lepéchoux, Frank Aboubakar Nana, Angela Botticella, Julien Adam, Roberto Ferrara, Anas Gazzah, Maud Ngocamus1, Jean-Charles Soria, Benjamin Besse
- Abstract
Loading... -
+
P2.13-25 - Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland
16:45 - 18:00 | Presenter: Paula Scott | Author(s): Caroline Clark, Keith M Kerr, Tracy Petrie, Marianne Nicolson
- Abstract
Loading... -
+
P2.13-26 - Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI
16:45 - 18:00 | Presenter: Sandhya Sharma | Author(s): Chung-Shien Lee, Emily Miao, Nagashree Seetharamu
- Abstract
Loading... -
+
P2.13-27 - Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC
16:45 - 18:00 | Presenter: Ross Soo | Author(s): Isaac Kah Siang Ng, Nesaretnam Barr Kumarakulasinghe, Nicholas Syn
- Abstract
Loading... -
+
P2.13-28 - Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC
16:45 - 18:00 | Presenter: Christi Marja Johanna Steendam | Author(s): Ron H.N. Van Schaik, Esther Oomen - De Hoop, Peggy N. Atmodimedjo, Evert De Jonge, Jan H. Von Der Thüsen, Winand N.M. Dinjens, Erik Jan Dubbink, Joachim G.J.V. Aerts
- Abstract
Loading... -
+
P2.13-29 - IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification
16:45 - 18:00 | Presenter: Xiyi Lu | Author(s): Xiaomeng Wang, Jiaqi Yao, Shidai Jin, Renhua Guo
- Abstract
Loading... -
+
P2.13-30 - High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study
16:45 - 18:00 | Presenter: Shucai Zhang | Author(s): Xi Li, Li Zhang, Jiang Da, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Guangyu An, Cuiying Zhang, Xingsheng Hu, Gang Cheng, Huaqing Wang, Zhihai Han, Xiaohui He, Junli Liu, Li Liang
- Abstract
Loading... -
+
P2.13-31 - p.(Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment – Analysis in a Cohort of 1841 Polish NSCLC Patients
16:45 - 18:00 | Presenter: Joanna Chorostowska-Wynimko | Author(s): Katarzyna Duk, Paulina Skrońska, Michał Skroński, Aneta Zdral, Dariusz Kowalski, Piotr Rudzinski, Renata Langfort, Tadeusz Orłowski
- Abstract
Loading... -
+
P2.13-32 - TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
16:45 - 18:00 | Presenter: Jouhara Chouitar | Author(s): Sylvie Vincent, Rachael Brake, Shuanglian Li
- Abstract
Loading... -
+
P2.13-33 - A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC
16:45 - 18:00 | Presenter: Donna Graham | Author(s): Matthew G Krebs, Mahmood Ayub, Jo Dransfield, Hannah Frost, Sreeja Aruketty, Bedirhah Kilerci, Andrew Wallace, Rajender Kamboj, Dhananjay Bakhle, Venkata Palle, Sharad Sharma, Narendra Maharaj, Rajesh Kumawat, Mandar Bhonde, Kristopher Frese, Caroline Dive, Dominic Rothwell, Ged Brady
- Abstract
Loading... -
+
P2.13-34 - Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Xiyi Lu | Author(s): Xinyin Liu, Renhua Guo
- Abstract
Loading... -
+
P2.13-35 - Inhibition of H3K27 Demethylation is Toxic in Poorly Differentiated Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Timothy L Lochmann | Author(s): Marissa L Calbert, Krista M Powell, Cyril H Benes, Hisashi Harada, Anthony C Faber
- Abstract
Loading... -
+
P2.13-36 - Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China
16:45 - 18:00 | Presenter: Shun Lu | Author(s): Yongfeng Yu
- Abstract
Loading... -
+
P2.13-37 - Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway
16:45 - 18:00 | Presenter: Xin Lyu | Author(s): Lizhong Zeng, Jingyan Yuan, Xia Meng, Ruiying Sun, Boxuan Liu, Ying Bai, Xuan Liu, Zongfang Li, Shuanying Yang
- Abstract
Loading... -
+
P2.13-38 - Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients with Lung Cancer
16:45 - 18:00 | Presenter: Emily Miao | Author(s): Stephen Eng, Chung-Shien Lee, Nagashree Seetharamu, Kevin Sullivan
- Abstract
Loading... -
+
P2.13-39 - A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Zorawar Noor | Author(s): Jonathan W. Goldman, William E. Lawler, Diane Melancon, Bijoy Telivala, Fadi Braiteh, Brian A. Dicarlo, Kathleen Kennedy, Diego Martinez, Brad Adams, Xiaoyan Wang, Benjamin Jones, Edward B Garon
- Abstract
Loading... -
+
P2.13-40 - ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)
16:45 - 18:00 | Presenter: Valdimir Hanes | Author(s): Nick Thatcher, Jerome Goldschmidt Jr., Michael Thomas, Michael Schenker, Zhiying Pan
- Abstract
Loading... -
+
P2.13-41 - A Novel Mitochondria-Based Targeting to Restore Therapeutic Response in Cisplatin- and Gefitinib-Resistant Human Lung Cancer Cells
16:45 - 18:00 | Presenter: Qinghua Zhou
- Abstract
Loading... -
+
P2.13-42 - Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Joop de Langen | Author(s): Bianca Van Veggel, Anthonie Van Der Wekken, Sayed MS Hashemi, Robin Cornelissen, Kim Monkhorst, Danielle Heideman, Teodoa Radonic, Ed MD Schuuring, Egbert F Smit
- Abstract
Loading... -
+
P2.13-43 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
16:45 - 18:00 | Presenter: Pasi A Jänne | Author(s): Helena Yu, Melissa L. Johnson, Conor E. Steuer, Michele Vigliotti, Nicole Shipitofsky, Ferdinand Morales Guevara, Shuquan Chen, Channing Yu
- Abstract
Loading... -
+
P2.13-44 - Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
16:45 - 18:00 | Presenter: Paul K. Paik | Author(s): Linda Ahn, Michelle S Ginsberg, Daniel McFarland, L. Austin Doyle, Charles M. Rudin
- Abstract
Loading... -
+
P2.13-45 - SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
16:45 - 18:00 | Presenter: Lecia Sequist | Author(s): Pasi A Jänne, Frances A Shepherd, Rudolf M Huber, Jhanelle Elaine Gray, Enriqueta Felip, Maurice Pérol, Fred R. Hirsch, Daniel S.W. Tan, Kim Caliri, Sara Ghassemifar, Ben Wang, Walid Kamoun, Sergio Santillana, Vasileios Askoxylakis, J Marc Pipas
- Abstract
Loading... -
+
P2.13-46 - Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients
16:45 - 18:00 | Presenter: Yang W. Shao | Author(s): Ruoying Yu, Hairong Bao, Sai-Hong Ignatius Ou, Xue Wu
- Abstract
Loading...